New drug targets rare cancer mutation in early trial
NCT ID NCT07038369
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults will take part, and some may also receive a second drug called fulvestrant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATV-1601 (a targeted drug that blocks a specific cancer-driving protein called AKT1 E17K)
- What this could lead to
- If this works, it could offer a new treatment option for people with certain advanced cancers that have a specific AKT1 mutation.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not be effective or safe in larger studies. Side effects are unknown and the mutation is rare.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Florida Cancer Specialists & Research Institute - Lake Mary
Lake Mary, Florida, 32746, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
START Madrid - CIOCC
Madrid, 28050, Spain
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- A web program may ease the emotional toll of chemotherapy hair loss